BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 27250026)

  • 1. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer.
    Jadaliha M; Zong X; Malakar P; Ray T; Singh DK; Freier SM; Jensen T; Prasanth SG; Karni R; Ray PS; Prasanth KV
    Oncotarget; 2016 Jun; 7(26):40418-40436. PubMed ID: 27250026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer.
    Huang NS; Chi YY; Xue JY; Liu MY; Huang S; Mo M; Zhou SL; Wu J
    Oncotarget; 2016 Jun; 7(25):37957-37965. PubMed ID: 27191888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.
    Zuo Y; Li Y; Zhou Z; Ma M; Fu K
    Biomed Pharmacother; 2017 Nov; 95():922-928. PubMed ID: 28915533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
    Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer.
    Ou X; Gao G; Bazhabayi M; Zhang K; Liu F; Xiao X
    J Cancer Res Ther; 2019; 15(7):1597-1602. PubMed ID: 31939443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer.
    Xu S; Sui S; Zhang J; Bai N; Shi Q; Zhang G; Gao S; You Z; Zhan C; Liu F; Pang D
    Int J Clin Exp Pathol; 2015; 8(5):4881-91. PubMed ID: 26191181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
    Zheng S; Yang L; Zou Y; Liang JY; Liu P; Gao G; Yang A; Tang H; Xie X
    J Hematol Oncol; 2020 Mar; 13(1):17. PubMed ID: 32138762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development.
    Jin C; Yan B; Lu Q; Lin Y; Ma L
    Tumour Biol; 2016 Jun; 37(6):7383-94. PubMed ID: 26676637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway.
    Jin Y; Feng SJ; Qiu S; Shao N; Zheng JH
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3176-3184. PubMed ID: 28770968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.
    Gordon MA; Babbs B; Cochrane DR; Bitler BG; Richer JK
    Mol Carcinog; 2019 Feb; 58(2):196-205. PubMed ID: 30294913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer.
    Pang EJ; Yang R; Fu XB; Liu YF
    Tumour Biol; 2015 Apr; 36(4):2403-7. PubMed ID: 25481511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA Highly Up-regulated in Liver Cancer Predicts Unfavorable Outcome and Regulates Metastasis by MMPs in Triple-negative Breast Cancer.
    Shi F; Xiao F; Ding P; Qin H; Huang R
    Arch Med Res; 2016 Aug; 47(6):446-453. PubMed ID: 27986124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death.
    Beltrán-Anaya FO; Romero-Córdoba S; Rebollar-Vega R; Arrieta O; Bautista-Piña V; Dominguez-Reyes C; Villegas-Carlos F; Tenorio-Torres A; Alfaro-Riuz L; Jiménez-Morales S; Cedro-Tanda A; Ríos-Romero M; Reyes-Grajeda JP; Tagliabue E; Iorio MV; Hidalgo-Miranda A
    Mol Oncol; 2019 Apr; 13(4):909-927. PubMed ID: 30648789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    De Palma FDE; Del Monaco V; Pol JG; Kremer M; D'Argenio V; Stoll G; Montanaro D; Uszczyńska-Ratajczak B; Klein CC; Vlasova A; Botti G; D'Aiuto M; Baldi A; Guigó R; Kroemer G; Maiuri MC; Salvatore F
    Pharmacol Res; 2020 Nov; 161():105249. PubMed ID: 33068730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.
    Mou E; Wang H
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31399501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
    Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
    Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.